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Since the declaration of Coronavirus Disease 2019 (COVID-19) pandemic on 11 March 2020 by the WHO, an accumulated number of at least 70 461 926 confirmed cases and 1 599 704 deaths in 216 countries/territories has been recorded by 14/12/2020 [1]. In line with the established WHO global research road-
map for COVID-19 [2], the UNCOVER (Usher Network for COVID-19 Evidence Reviews) group commit-
ted to summarise COVID-19 evidence-based reviews for policymakers, clinicians and researchers to respond 
quickly to the outbreak of COVID-19. To assist in policy and clinical decision making and to avoid duplicate 
efforts, we created the UNCOVER registry of reviews, an online collection of 
published and ongoing reviews. Details of the UNCOVER registry have been 
previously reported [3] and here we present an update in relation to the main 
characteristics of the current collection.
As of 16/11/2020, the UNCOVER registry includes 2334 different types of 
published or ongoing reviews (https://www.ed.ac.uk/usher/uncover/register-
of-reviews), including 1676 systematic reviews and meta-analyses, 393 rapid 
reviews, 113 scoping reviews, four umbrella reviews, 14 narrative reviews and 
134 protocols (Figure 1, Panel A) [4]. The website has been accessed a total of 9094 times with 4169 times 
abstract viewing and 3150 times completed review viewing. The publication sources for COVID-19 evidence-
based reviews in the UNCOVER register include PubMed (n = 1450), WHO COVID-19 database (n = 384), 
medRxiv (n = 408), and other websites (n = 92) such as the national collaborating centre for methods and tools 
[5] and The Centre for Evidence-Based Medicine [6] (Figure 1, Panel B).
Research topics of indexed reviews were categorised thematically according to McMaster University COVI-
DEND (COVID-19 Evidence Network to support Decision-making) taxonomy into five groups: 1) Clinical 
management of COVID-19 and pandemic-related health issues (n = 1755, 75.2%); 2) Public-health measures 
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(n = 342, 14.7%); 3) Health-system arrangements (n = 85, 3.6%); 4) Economic and social responses (n = 59, 
2.5%); 5) Other reviews (n = 93, 4.0%) (Figure 2, Panel A) [7]. We further categorised each review into 22 
subgroups under the five COVIDEND groups (Table 1):
Figure 1. Review types and review sources of the included reviews in the UNCOVER registry. Panel A. Review types.
Panel B. Review sources. medRxiv preprints were replaced with the peer-reviewed publications once they have been 
published in peer-reviewed journals; the review types displayed directly in the searching results of the website and the 
review sources can be accessed through the filter.
1 Panel A 1 Panel B
Table 1. Categories and selected sub-categories of research topics of reviews included in the UNCOVER registry.
Clinical management of 
COVID-19 and pandemic-






Economic and social 
responses (n = 59)
Other reviews(n = 93)
Clinical features (n = 372) Infection (n = 37) Health care resource 
arrangement (n = 38)
Education (n = 11) Comparison of COVID-19, 
SARS, and MERS (n = 32)
• Symptoms • Infection route • Allocation of ICU beds
and ventilators
• Public health education • Viral load dynamics
• Biochemical indicators • Secondary infection • Primary health care Social consequences (n = 29) • Duration of viral shedding
Clinical tests (n = 147) Transmission (n = 115) • Orthodontic care • Bereavement Published articles (n = 25)
• Effectiveness of diagnostic
test
• Transmission route • Neurosurgical practice • Domestic violence • Methodological quality of
COVID-19 systematic reviews
• CT imaging and findings • R number Clinical departments 
arrangement (n = 42)
Economy (n = 7) Coronavirus genomic RNA 
packaging (n = 19)
• Lung ultrasound • Incubation • Hospital surge capacity
planning
Governance (n = 6) Others (n = 17)
Clinical treatments (n = 454) Public health burden (n = 8) Others (n = 5) Others (n = 6)
• Hydroxychloroquine • Seroprevalence
• Remdesivir • Mortality
• Tocilizumab Prevention and control 
measures (n = 109)




Clinical trials (n = 15) • Social distancing
• Vaccines Living habits (n = 28)
• Drugs • Smoking
Clinical outcomes (n = 123) • Physical activity
• Discharge rate, and fatality
rate
Environment (n = 7)
• Recurrence Others (n = 38)
•  Critical complications
Clinical risk prediction 
models (n = 15)
• Model development and 
validation
COVID-19 and 
comorbidities (n = 480)
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Clinical management of COVID-19 and pandemic-related health issues, a total of 1755 reviews were di-
vided into seven subgroups: Clinical features (n = 372); Clinical tests (n = 147); Clinical treatments (n = 454); 
Clinical trials (n = 15); Clinical outcomes (n = 123); Clinical risk prediction models (n = 15); and COVID-19 
and comorbidities (n = 480).
Public-health measures, a total of 342 reviews were divided into six subgroups: Infection (n = 37); Transmis-
sion (n = 115); Public health burden (n = 8); Prevention and control measures (n = 109); Living habits (n = 28); 
Environmental impact (n = 7).
Health-system arrangements, a total of 85 reviews were divided into two subgroups: Health care resource 
arrangement (n = 38); Clinical department arrangement (n = 42).
Figure 2. Number of reviews and distribution of review topics of the UNCOVER registry over time Panel A. Number of reviews entered in 
UNCOVER registry by the month of entry. Panel B. Proportion of review topics entered in the UNCOVER registry by the month of entry. 
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Economic and social responses, a 
total of 59 reviews were divided into 
four subgroups: Education (n = 11); 
Social consequences (n = 29); Econo-
my (n = 7); Governance (n = 6).
Other reviews, a total of 93 reviews 
were divided into three subgroups: 
Comparison of COVID-19, SARS, 
and MERS (n = 32); Publications 
(n = 25); Coronavirus genomic RNA 
packaging (n = 19).
On average, we include 292 reviews 
per month. There has been an in-
creasing trend in the number of pub-
lished or ongoing COVID-19 reviews 
and the composition of research top-
ics has changed over time. Figure 2, Panel B, shows that the proportion of reviews on clinical management 
of COVID-19 and pandemic-related health issues increased from April to September (from 60.3% to 82.3%) 
but the proportion has been steadily declining since September to 74.4% and 72.4% for October and Novem-
ber respectively. In contrast, the proportion of reviews on public health measures decreased from May to Sep-
tember except for August (from 21.4% to 10.5%) and the proportion was higher in October and November 
(16.8% and 13.9% respectively). For the other three topics, the trend is fluctuating. We further categorized 
the pandemic into three time periods: 1) before June 2020, where the main contributors were Western Pacific, 
Americas and Europe but the case incidence was kept in relatively low levels; 2) June-September 2020, where 
the number of new cases continued to increase and the main contributors were Americas and South-East Asia; 
and 3) October 2020 to now, where the number of cases increased sig-
nificantly driven by the second outbreak in Americas and Europe. From 
Figure 2, Panel C, the highest proportion of reviews on clinical manage-
ment of COVID-19 and pandemic-related health issues was in June to 
September while the proportion of reviews on public health measures 
was relatively high in periods before June and after September. The pro-
portion of reviews on economic and social responses has been increas-
ing, but they still account for a small proportion.
In summary, a total of 2334 COVID-19 evidence-based reviews have been indexed in UNCOVER registry, 
more than half of the reviews included were from PubMed, and over two-thirds of the included reviews were 
systematic reviews and meta-analyses. The research topics concentrated on clinical features, tests, treatment 
and outcomes, COVID-19 comorbidities, and the transmission, prevention and control of COVID-19. Although 
we have seen an increasing trend for reviews on economic and social responses across the three time periods, 
the total number remains very low and not in line with its importance.
The registry offers the opportunity to explore the aforementioned topics using state of the art methodologies 
in evidence-based research (such as umbrella reviews with evidence synthesis and assessment of the risk of 
bias) [8-12]. This will provide policymakers, clinicians and researchers a clear understanding of broad topic 
areas in relation to COVID-19.
Photo: Register of reviews from UNCOVER team, the University of Edinburgh (from the author’s own collection, 
used with permission).
The research topics of COVID-19 related 
reviews concentrated on clinical features, 
tests, treatment and outcomes, COVID-19 
comorbidities, and the transmission, pre-
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